


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Martin *et al.*
Serial No.: 10/717,049
Cust. No.: 24961
Filed: November 18, 2003
For: **HETEROCYCLIC
MODULATORS OF
NUCLEAR RECEPTORS**
Art Unit: Not assigned yet
Examiner: Not assigned yet

INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits of the Request for Continued Examination for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. The Form PTO-1449 (12 pages) is provided herewith. Copies of the references listed without an asterisk on the Form PTO-1449 are not provided herewith as they previously have been provided in connection with U.S. Serial No. 10/329,668, which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120.

The documents listed on the Form PTO-1449 are in the English language

U.S.S.N 10/717,049

Martin *et al.*

INFORMATION DISCLOSURE STATEMENT

with the exception of Items BV, CI, CJ, CK, CL, CM, CN, CO, CP, CS, and CT. Items BV, CL, CM, CN, CO, and CP (JP 200113617, JP 527356, JP 53129633, and JP 6234639, respectively), which are in the Japanese language, were provided with English language Derwent abstracts (Items DN, DO, DR, and DQ, respectively). Items CN and CP (JP 6220053 and JP 6293642, respectively), which are in the Japanese language, were provided with English language equivalents (Items AO and AR, respectively). Item CI (FR 1449800), which is in the French language, was provided with an English language STN abstract (Item FT). Item CK (FR 2117337), which is in the French language, was provided with an English language Derwent abstract (Item DP). Items CJ and CS (DE 1908570 and WO 9104974, respectively), which are in the German language, were provided with English language equivalents (Items H and AL, respectively). Item DA (Augustin *et al.*), which is in the German language, was provided with an English language STN abstract (Item FV). Items DX and DY (Fedetov, K.V. and Fedetov *et al.*, respectively), which are in the Russian language, were provided with English language STN abstracts (Items FS and FU, respectively). Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following copending U.S. and International applications, which are commonly owned and/or have one or more inventors in common in the instant application:

<u>U.S.S.N.(App. no.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
10/447,302	5/26/03	Unknown

Applicant also makes known to the Examiner the following now-expired provisional applications, and all available data concerning the corresponding U.S. utility and PCT applications filed therefrom:

<u>Provisional:</u>			<u>Corresponding U.S. Utility:</u>		
<u>Appl. No.</u>	<u>Filing Date</u>	<u>Docket No.</u>	<u>Appl. No.</u>	<u>Filing Date</u>	<u>Docket No.</u>
60/389,662	06/18/02	Unknown	Unknown	Unknown	Unknown

U.S.S.N 10/717,049

Martin *et al.*

INFORMATION DISCLOSURE STATEMENT


Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

* * *

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER EHRMAN WHITE & MCAULIFFE LLP

By:


Dale L. Rieger
Registration No. 43,045

Dated: January 13, 2004

Attorney Docket No. 38205-3001B

Address all correspondence to:

Stephanie Seidman, Esq.

HELLER EHRMAN WHITE & MCAULIFFE LLP


4350 La Jolla Village Drive, 7th floor

San Diego, CA 92122-1246

Telephone: 858 450-8400

Facsimile: 858 587-5360

email: sseidman@HEWM.com



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	R	E	2	8	8	1	9	05/18/76	Thompson	424	243	12/08/72
	B	0	1	2	0	1	3	7	08/29/02	Houze <i>et al.</i>	540	589	08/31/01
	C	0	1	3	2	2	2	3	09/19/02	Forman <i>et al.</i>	435	4	10/05/01
**	D	0	1	8	1	4	2	0	09/25/03	Bayne <i>et al.</i>	514	63	12/20/02
**	E	0	2	2	8	6	0	7	12/11/03	Wagner <i>et al.</i>	435	6	04/14/03
	F	2	3	8	8	9	6	3	01/21/38	Fre <i>et al.</i>	260	240	01/22/37
	G	2	4	5	4	6	2	9	11/23/48	Brooker	260	240	01/27/40
	H	3	6	2	7	5	3	4	12/14/71	Shiba <i>et al.</i>	96	135	02/21/68
	I	3	6	3	5	9	6	4	01/18/72	Skorcz <i>et al.</i>	260	247.1	02/10/69
	J	3	7	1	0	7	9	5	01/16/73	Higuchi <i>et al.</i>	128	260	09/29/70
	K	4	0	4	4	1	2	6	08/23/77	Cook <i>et al.</i>	424	243	07/09/76
	L	4	0	9	3	7	3	0	06/06/78	Butti <i>et al.</i>	424	270	06/28/76
	M	4	2	3	1	9	3	8	11/04/80	Monaghan <i>et al.</i>	260	343.5	06/15/79
	N	4	2	5	8	1	8	5	03/24/81	Nakao <i>et al.</i>	544	114	04/14/80
	O	4	3	2	8	2	4	5	05/04/82	Yu <i>et al.</i>	424	305	02/13/81
	P	4	3	4	6	2	2	7	08/24/82	Terahara <i>et al.</i>	560	119	06/05/81
	Q	4	3	5	8	6	0	3	11/09/82	Yu	560	2	04/16/81
	R	4	3	6	4	9	2	3	12/21/82	Cook <i>et al.</i>	424	46	04/30/81
	S	4	4	0	9	2	3	9	10/11/83	Yu	424	305	01/21/82

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

U.S. PATENT DOCUMENTS


EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	T	4	4	1	0	5	4	5	10/18/83	Yu <i>et al.</i>	424	305	05/10/82
	U	4	4	1	4	2	0	9	11/08/83	Cook <i>et al.</i>	424	243	06/13/77
	V	4	4	4	4	7	8	4	04/24/84	Hoffman <i>et al.</i>	424	279	12/18/80
	W	4	5	2	2	8	1	1	06/11/85	Eppstein <i>et al.</i>	514	2	07/08/82
	X	4	9	1	6	1	2	8	04/10/90	Jonas <i>et al.</i>	514	213	06/06/88
	Y	4	9	3	3	3	3	6	06/12/90	Martin <i>et al.</i>	514	222.5	08/09/88
	Z	5	0	3	3	2	5	2	07/23/91	Carter	53	425	07/30/90
	AA	5	0	5	2	5	5	8	10/01/91	Carter	206	439	07/27/90
	AB	5	0	7	0	0	1	2	12/03/91	Nolan <i>et al.</i>	435	6	03/30/88
	AC	5	0	7	1	7	7	3	12/10/91	Evans <i>et al.</i>	436	501	10/20/87
	AD	5	1	7	1	8	5	1	12/15/92	Kim <i>et al.</i>	544	50	03/25/91
	AE	5	1	7	7	0	8	0	01/05/93	Angerbauer <i>et al.</i>	514	277	11/26/91
	AF	5	2	2	1	6	2	3	06/22/93	Legocki <i>et al.</i>	435	252.3	07/19/89
	AG	5	2	7	3	9	9	5	12/28/93	Roth	514	422	02/26/91
	AH	5	2	8	3	1	7	3	02/01/94	Fields <i>et al.</i>	435	6	01/24/90
	AI	5	2	9	8	4	2	9	03/29/94	Evans <i>et al.</i>	436	501	12/10/91
	AJ	5	3	2	3	9	0	7	06/28/94	Kalvelage	206	531	03/15/93
	AK	5	3	5	4	7	7	2	10/11/94	Kathawala	514	414	11/24/93
	AL	5	4	1	4	0	8	8	05/09/95	Von Der Saal <i>et al.</i>	546	158	09/04/90

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AM	5	4	6	8	6	1	4	11/21/95	Fields <i>et al.</i>	435	6	02/01/94
	AN	5	4	7	6	9	4	5	12/19/95	Ikegawa <i>et al.</i>	548	152	10/19/93
	AO	5	6	1	8	8	3	1	04/08/97	Shishido <i>et al.</i>	514	366	05/16/94
	AP	5	6	5	0	2	8	9	07/22/97	Wood	435	8	01/31/94
	AQ	5	6	6	7	9	7	3	10/07/97	McElroy <i>et al.</i>	514	366	06/07/95
	AR	5	6	7	0	5	3	0	09/23/97	Chen <i>et al.</i>	514	366	06/07/95
	AS	5	6	7	4	7	1	3	10/07/97	McElroy <i>et al.</i>	435	69.7	06/02/95
	AT	5	6	8	3	8	8	8	11/04/97	Campbell	435	8	07/05/94
	AU	5	7	0	7	7	9	4	01/13/98	Fabricius	430	572	11/22/96
	AV	5	7	4	1	6	5	7	04/21/98	Tien <i>et al.</i>	435	18	03/20/95
	AW	5	7	5	7	6	6	1	05/26/98	Surville	364	506	07/01/94
	AX	5	8	4	3	7	4	6	12/01/98	Tatsumi <i>et al.</i>	435	189	01/13/97
	AY	5	9	5	5	6	0	4	09/21/99	Tsien <i>et al.</i>	540	222	10/21/97
	AZ	6	0	7	1	9	5	5	06/06/00	Elias <i>et al.</i>	514	475	02/25/99
	BA	6	1	8	4	2	1	5	02/06/01	Elias <i>et al.</i>	514	182	08/24/99
	BB	6	1	8	7	8	1	4	02/13/01	Elias <i>et al.</i>	514	531	10/29/99
	BC	6	2	9	1	6	7	6	09/18/01	Burke <i>et al.</i>	546	48	03/02/00
	BD	6	3	1	6	5	1	0	11/13/01	Sperber	521	94	04/05/00
	BE	6	4	1	6	9	5	7	07/09/02	Evans <i>et al.</i>	435	7.1	10/24/00

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**

FORM PTO-1449

ATTY. DOCKET NO.
38205-3001BSERIAL NO.
10/717,049CONFIRM NO.
Unassigned.APPLICANT
Martin *et al.*CUSTOMER NO.
24961FILING DATE
November 18, 2003GROUP
Unassigned.LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	BF	6	4	5	2	0	3	2	09/17/02	Beard <i>et al.</i>	556	413	06/09/00
	BG	6	4	5	8	7	8	9	10/01/02	Forood <i>et al.</i>	514	235.5	09/29/99
	BH	6	5	2	1	6	6	6	02/18/03	Sircar <i>et al.</i>	514	576	07/19/00

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	BI	0	0	1	7	3	3	4	03/30/00	PCT				
	BJ	0	0	2	5	1	3	4	05/04/00	PCT				
	BK	0	0	3	7	0	7	7	06/29/00	PCT				
	BL	0	0	4	0	9	6	5	07/13/00	PCT				
	BM	0	0	4	2	0	3	1	07/20/00	PCT				
	BN	0	0	4	9	9	9	2	08/31/00	PCT				
	BO	0	0	5	7	9	1	5	10/05/00	PCT				
	BP	0	0	7	6	5	2	3	12/21/00	PCT				
	BQ	0	0	7	8	9	7	2	12/28/00	PCT				
	BR	0	1	1	7	9	9	4	03/15/01	PCT				
	BS	0	1	2	0	1	3	7	03/22/01	PCT				
	BT	0	1	2	3	8	8	7	04/05/01	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	BU	0	1	6	0	8	1	8	08/23/01	PCT				
	BV	20	01	1	3	6	1	7	01/19/01	JP				+
	BW	0	1	8	2	9	1	7	11/08/01	PCT				
	BX	02	0	6	4	1	2	5	08/22/02	PCT				
	BY	02	0	7	2	5	9	8	09/19/02	PCT				
	BZ	0	2	1	1	7	0	8	02/14/02	PCT				
*	CA	0	3	0	5	9	8	84	07/24/03	PCT				
*	CB	0	3	0	6	0	0	78	07/24/03	PCT				
*	CC	0	3	0	7	6	4	18	09/18/03	PCT				
*	CD	0	3	0	9	9	8	21	12/04/03	PCT				
*	CE	0	3	1	0	6	4	35	12/24/03	PCT				
	CF	0	4	5	4	3	3	0	04/12/91	EP				
	CG	0	5	1	0	2	3	5	04/26/91	EP				
	CH	0	9	8	5	6	8	3	09/09/99	EP				
	CI	1	4	4	9	8	0	0	07/02/64	FR				+
	CJ	1	9	0	8	5	7	0	02/20/69	DE				X
	CK	2	1	1	7	3	3	7	03/12/71	FR				+
	CL	5	2	7	3	5	6		02/05/93	JP				+
	CM	53	1	2	9	6	3	3	11/11/78	JP				+

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	CN	6	2	2	0	0	5	3	08/09/94	JP				X
	CO	6	2	3	4	6	3	9	08/23/94	JP				+
	CP	6	2	9	3	6	4	2	10/21/94	JP				X
	CQ	8	4	0	2	1	3	1	06/07/84	PCT				
	CR	8	6	0	3	7	4	9	07/03/86	PCT				
	CS	9	1	0	4	9	7	4	04/18/91	PCT				X
	CT	9	5	1	8	3	8	0	07/06/95	PCT				
	CU	9	7	0	7	1	0	1	02/27/97	PCT				
	CV	9	8	3	2	4	4	4	07/30/98	PCT				
	CW	9	9	2	7	3	6	5	06/03/99	PCT				

+ = An English Derwent Abstract or STN Chem Abstract is provided.

X = An English language equivalent is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CX	"Hypolipidemics, HMG-CoA Reductase Inhibitors," <i>Physicians' Desk Reference</i> (PDR), 50th Ed, (Medical Economics Co), pp. 216 (1996)
CY	Alberti <i>et al.</i> , "Structural characterisation of the mouse nuclear oxysterol receptor genes LXR α and LXR β ", <i>Gene</i> , <u>243</u> :93-103 (2000)
CZ	Ansel, H.C., (Eds.), in <i>Introduction to Pharmaceutical Dosage Forms Fourth Edition</i> , Philadelphia: Lea & Febiger, pp.125 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


DA	Augustin <i>et al.</i> , "Umsetzung des Thiazolo [3,2-a] benzimidazol-3-ons mit Elektrophilen [Reactions of thiazolo [3,2-a]benzimidazol-3-one with electrophiles]", <i>Zeitschrift fur Chemie</i> , <u>29(6)</u> :206-207 (1989)
DB	Barrett-Connor, "Epidemiology, Obesity, and Non-Insulin-Dependent Diabetes Mellitus", <i>Epidemiologic Reviews</i> , <u>11</u> :172-181 (1989)
DC	Bellec <i>et al.</i> , "Dicationic State of Dithiadiazafulvalene within a TCNQ Charge-Transfer Complex: Generation and Characterization", <i>Chem. Mater.</i> , <u>11</u> :3147-3153 (1999)
DD	Berger <i>et al.</i> , "Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells", <i>Gene</i> , <u>66</u> :1-10 (1988)
DE	Bronstein <i>et al.</i> , "1,2-Dioxetanes: Novel Chemiluminescent Enzyme Substrates. Applications to Immunoassays", <i>Journal of Bioluminescence and Chemiluminescence</i> , <u>4</u> :99-111 (1989)
DF	Carceller <i>et al.</i> , "Design, Synthesis, and Structure-Activity Relationship Studies of Novel 1-[(1-Acyl-4-piperidyl)methyl]-1 <i>H</i> -2-methylimidazo[4,5- <i>c</i>] pyridine Derivatives as Potent, Orally Active Platelet-Activating Factor Antagonists", <i>J. Med. Chem.</i> , <u>39</u> :487-493 (1996)
DG	Chiang <i>et al.</i> , "Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7 α -Hydroxylase Gene (<i>CYP7A1</i>) Transcription", <i>Journal of Biological Chemistry</i> , <u>275(15)</u> :10918-10924 (2000)
DH	Chiasson <i>et al.</i> , "The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus", <i>Ann. Intern. Med.</i> , <u>121</u> :928-935 (1994)
DI	Chiba <i>et al.</i> , "Distinct Retinoid X Receptor-Retinoic Acid Receptor Heterodimers Are Differentially Involved in the Control of Expression of Retinoid Target Genes in F9 Embryonal Carcinoma Cells", <i>Molecular and Cellular Biology</i> , <u>17(6)</u> :3013-3020 (1997)
DJ	Coniff, R. and A. Krol, "Acarbose: A Review of US Clinical Experience", <i>Clinical Therapeutics</i> , <u>19(1)</u> :16-26 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


DK	Coniff <i>et al.</i> , "Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus", <i>American Journal of Medicine</i> , <u>98</u> :443-451 (1995)
DL	Dains <i>et al.</i> , "The Reactions of the Formamidines. VIII. Some Thiazolidone Derivatives", <i>J. Am. Chem. Soc.</i> , <u>43</u> :613-618 (1921)
DM	Davis, J.A. and F.B. Dains, "Some Alkyl Derivatives of Certain Aryl Substituted Thiazolidones", <i>J. Am. Chem. Soc.</i> , <u>57</u> :2627-2630 (1935)
DN	Derwent WPI Acc. No. 13863260 citing Japanese Patent 2001-13617, "Silver halide emulsion, silver halide photosensitive material and thermally developable photosensitive material".
DO	Derwent WPI Acc. No. 9387756 citing Japanese Patent 5-27356, "Silver halide photographic material - contains silver halide particles spectrally sensitised with novel merocyanine dye".
DP	Derwent# 000911469, WPI Acc. No. 1972-71638T/197245 (citing French Patent Number 2117337), "Merocyanine dye sensitizers - contg basic and acidic gps for silver halide emulsions".
DQ	Derwent# 010039860, WPI Acc. No. 1994-307571/199438 (citing Japanese Patent Number 6-234639), "Immunosuppressant contg. Rhodacyanine deriv. - useful in treatment and prevention of e.g. organ, tissue or bone marrow transplant rejection, systemic lupus erythematosus and auto-immune diseases".
DR	Derwent# 002077750, WPI Acc. No. 1978-908270A/197850 (citing Japanese Patent Number 53-129633), "Antistatic silver halide photographic material - contg. oxazolidine deriv. as UV absorber".
DS	Dogan <i>et al.</i> , "Synthesis and NMR Studies of Chiral 4-Oxazolidinones and Rhodanines", <i>Tetrahedron</i> , <u>48</u> (35):7157-7164 (1992)
DT	Drobnica <i>et al.</i> , "Isothiocyanates. XXXII. Microsynthesis of 3-Substituted Rhodanines", <i>Chem. Zvest</i> , <u>26</u> :538-542 (1972)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


DU	El-Bahaie <i>et al.</i> , "Synthesis of some New Thienopyrimidines containing 4-Thiazolidinone Moiety", <i>J. Indian Chem. Soc.</i> , Vol LXV:695-698 (1988)
DV	Evans, R.M., "The Steroid and Thyroid Hormone Receptor Superfamily", <i>Science</i> , 240:889-895 (1988)
DW	Fedotov, K.V. and N.N. Romanov "Mesoionic Compounds with a Bridged Nitrogen Atom. 18. Cyclization of (2-Quinazolinylthio) Acetic Acids", <i>Khim Geterotsilcl. Soedin.</i> (6):678-83 (1989) English language edition, [Translated from Russian into English from <i>Khimiya Geterotsiklicheskih Soedinenii</i> , 6:817-822 (1989)]
DX	Fedotov, K.V., "[Polymethine dyes with 3-oxo-2, 3-dihydrothiazole [3,2-a] pyrimidium nucleus]," in <i>Ukr. Khim Zh. (Russian Edition)</i> , 52(5):514-519 (1986)
DY	Fedotov <i>et al.</i> , "[Mesoionic compounds with a nitrogen bridging atom 12. Study of the cyclization of (2-pyrimidinylthio) acids]," in <i>Khim. Geterotsilcl. Soedin</i> , 7:969-73 (1984)
DZ	Flier, J.S., "Insulin Receptors and Insulin Resistance", <i>Ann. Rev. Med.</i> , 34:145-160 (1983)
EA	Forman <i>et al.</i> , "Identification of a Nuclear Receptor That is Activated by Farnesol Metabolites", <i>Cell</i> , 81:687-693 (1995)
EB	Gangjee <i>et al.</i> , "Synthesis and Biological Activities of Tricyclic Conformationally Restricted Tetrahydropyrido Annulated Furo [2,3-d] pyrimidines as Inhibitors of Dihydrofolate Reductases", <i>J. Med. Chem.</i> , 41:1409-1416 (1998)
EC	Garcia <i>et al.</i> , "Morbidity and Mortality in Diabetics in the Framingham Population", <i>Diabetes</i> , 23:105-111 (1974)
ED	Glass, C.K., "Differential Recognition of Target Genes by Nuclear Receptor Monomers, Dimers, and Heterodimers", <i>Endocrine Reviews</i> , 15(3):391-407 (1994)
EE	Glickman <i>et al.</i> , "A Comparison of ALPHAScreen, TR-FRET, and TRF as Assay Methods for FXR Nuclear Receptors", <i>Journal of Biomolecular Screening</i> , 7(1):3-10 (2002)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS



FORM PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EF	Gorman <i>et al.</i> , "Recombinant Genomes Which Express Chloramphenicol Acetyltransferase in Mammalian Cells", <i>Molecular and Cellular Biology</i> , <u>2(9)</u> :1044-1051 (1982)
EG	Greenberg, M.M. and J.D. Kahl, "Template-Free Segmental synthesis of Oligonucleotides Containing Nonnative Linkages", <i>J. Org. Chem.</i> , <u>66</u> :7151-7154 (2001)
EH	Haffner, S.M., "Management of Dyslipidemia in Adults with Diabetes", <i>Diabetes Care</i> , <u>21(1)</u> :160-178 (1998)
EI	Heyman <i>et al.</i> , "9-Cis Retinoic Acid is a High Affinity Ligand for the Retinoid X Receptor", <i>Cell</i> , <u>68</u> :397-406 (1992)
EJ	Howard <i>et al.</i> , "Lipoprotein Composition in Diabetes Mellitus", <i>Atherosclerosis</i> , <u>30</u> :153-162 (1978)
EK	Humphlett, W.J., and R.W. Lamon, "4-Thiazoline-2-thiones. I. The Structure of Intermediate 4-Hydroxythiazolidine-2-thiones", <i>J. Org. Chem.</i> , <u>29</u> :2146-2148 (1964)
EL	IUPAC-IUB Commission on Biochemical Nomenclature Abbreviated Nomenclature of Synthetic Polypeptides (Polymerized Amino Acids) Revised Recommendations (1971)", <i>Biochemistry</i> , <u>11(5)</u> :942-944 (1972)
EM	Iwamoto <i>et al.</i> , "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly controlled by Sulphonylurea Therapy Alone", <i>Diabetic Medicine</i> , <u>13</u> :365-370 (1996)
EN	Janowski <i>et al.</i> , "An oxysterol signalling pathway mediated by the nuclear receptor LXR α ", <i>Nature</i> , <u>383</u> :728-731 (1996)
EO	Joslin, E.P., "Arteriosclerosis and Diabetes", <i>Annals of Clinical Medicine</i> , <u>Vol V. No. 12</u> : 1061-1080 (1927)
EP	Kain, S.R., "Use fo Secreted Alkaline Phosphatase as a Reporter of Gene Expression in Mammalian Cells, <i>Methods in Molecular Biology</i> , <u>63</u> :49-60 (1997)
EQ	Kaplan, <i>et al.</i> (Eds.), "Cardiovascular Diseases", in <i>Health and Human Behavior</i> , New York: McGraw-Hill, Inc. pp. 206-242 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**

FORM PTO-1449

ATTY. DOCKET NO.
38205-3001BSERIAL NO.
10/717,049CONFIRM NO.
Unassigned.APPLICANT
Martin *et al.*CUSTOMER NO.
24961FILING DATE
November 18, 2003GROUP
Unassigned.LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

ER	Kassab, R.R. "Some Reactions with 2-Imino 4-Thiazolidone", <i>Al-Azhar Bull. Sci.</i> , <u>8(1)</u> : 1-6 (1997)
ES	Katritzky <i>et al.</i> , "Syntheses of 2-Alkylamino- and 2-Dialkylamino-4, 6-diarylpyridines and 2, 4, 6-Trisubstituted Pyrimidines Using solid-Phase-Bound Chalcones", <i>J. Comb. Chem.</i> , <u>2</u> :182-185 (2000)
ET	Katritzky <i>et al.</i> (Eds.), "Thiazoles and their Benzo Derivatives," <i>Comprehensive Heterocyclic Chemistry II: a review of the literature 1982-1985: the structure, reactions, synthesis, and uses of heterocyclic compounds</i> Netherlands: Elsevier Science, Ltd. pp.316-321 (1996) [CD-ROM Supplement]
EU	Knowler <i>et al.</i> , "Obesity in the Pima Indians: its magnitude and relationship with diabetes", <i>Am. J. Clin. Nutr.</i> , <u>53</u> :1543S-1551S (1991)
EV	Kwiterovich, Jr., P.O. "State-of-the-art Update and Review: Clinical Trials of Lipid-Lowering Agents", <i>Am. J. Cardiol.</i> , <u>82(12A)</u> :3U-17U (1998)
EW	Laakso, M. and S. Lehto, "Epidemiology of macrovascular disease in diabetes," <i>Diabetes Reviews</i> , <u>5(4)</u> :294-315 (1997)
EX	Lehmann <i>et al.</i> , "Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway", <i>Journal of Biological Chemistry</i> , <u>272(6)</u> :3137-3140 (1997)
EY	Levin <i>et al.</i> , "9- <i>Cis</i> retinoic acid stereoisomer binds and activates the nuclear receptor RXR α ", <i>Nature</i> , <u>355</u> :359-361 (1992)
EZ	Mahler, R.J. and M.L. Adler, "Type 2 Diabetes Mellitus: Update on Diagnosis, Pathophysiology, and Treatment", <i>Journal of clinical Endocrinology and Metabolism</i> , <u>84(4)</u> :1165-1171 (1999)
FA	Makishima <i>et al.</i> , "Identification of a Nuclear Receptor for Bile Acids", <i>Science</i> , <u>284</u> :1362-1365 (1999)
FB	Mangelsdorf <i>et al.</i> , "The RXR Heterodimers and Orphan Receptors", <i>Cell</i> , <u>83</u> :841-850 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**

FORM PTO-1449

ATTY. DOCKET NO.
38205-3001BSERIAL NO.
10/717,049CONFIRM NO.
Unassigned.APPLICANT
Martin *et al.*CUSTOMER NO.
24961FILING DATE
November 18, 2003GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


FC	Mangelsdorf <i>et al.</i> , "Characterization of three RXR genes that mediate the action of 9- <i>cis</i> retinoic acid", <i>Genes and Development</i> , <u>6</u> :329-344 (1992)
FD	Mehta, M. R. and J.P. Trivedi, "Synthesis of 2,3-disubstituted-4-thiazolidinones and 3,5-diaminothiophene-2-carboxylic acid derivatives", <i>Indian Journal of Chemistry</i> , <u>29B</u> :1146-1153 (1990)
FE	Mukherjee <i>et al.</i> , "Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α ", <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <u>81</u> :217-225 (2002)
FF	Nogard, <i>Medicinal Chemistry A Biochemical Approach</i> , Oxford University Press, New York, pp. 388-392 (1985).
FG	O'Malley, B.W. "Editorial: Did Eucaryotic Steroid Receptors Evolve from Intracrine Gene Regulators?", <i>Endocrinology</i> , <u>125</u> :1119-1120 (1989)
FH	Owicki, "Fluorescence and Anisotropy in High Throughput Screening: Perspectives and Primer," <i>Journal of Biomolecular Screening</i> , <u>5</u> (5):297-306 (2000)
FI	Parks <i>et al.</i> , "Bile Acids: Natural Ligands for an Orphan Nuclear Receptor", <i>Science</i> , <u>284</u> :1365-1368 (1999)
FJ	Peet <i>et al.</i> , "The LXRs: a new class of oxysterol receptors", <i>Curr. Opin. Genet. Dev.</i> , <u>8</u> (5):571-575 (1998)
FK	Peet <i>et al.</i> , "Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXR α ", <i>Cell</i> , <u>93</u> :693-704 (1998)
FL	Reaven, G.M., "Pathophysiology of Insulin Resistance in Human Disease", <i>Physiological Reviews</i> , <u>75</u> :473-486 (1995)
FM	Reaven, G.M., "Insulin Resistance and Human Disease: A Short History", <i>J. Basic and Clin. Phys. and Pharm.</i> , <u>9</u> :387-406 (1998)
FN	Seada <i>et al.</i> , "Synthesis and Biological Activity of Some New Thiazolidinones," <i>Indian J. Heterocycl. Chem.</i> , <u>3</u> :81-86 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


FO	Seol <i>et al.</i> , "Isolation of Proteins That Interact Specifically with the Retinoid X Receptor: Two Novel Orphan Receptors", <i>Molecular Endocrinology</i> , <u>9</u> :72-85 (1995)
FP	Sinal <i>et al.</i> , "Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis", <i>Cell</i> , <u>102</u> :731-744 (2000)
FQ	Song <i>et al.</i> , "Ubiquitous Receptor: Structures, Immunocytochemical Localization, and Modulation of Gene Activation by Receptors for Retinoic Acids and Thyroid Hormones", <i>Ann. N.Y. Acad. Sci.</i> , <u>761</u> :38-49 (1995)
FR	Still <i>et al.</i> , "Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution", <i>J. Org. Chem.</i> , <u>43</u> (14):2923-2925 (1978)
FS	STN (Chem. Abstracts) Document No. 105:154660, Chem. Abstract of Russian language article by Fedotov <i>et al.</i> , "Polymethine dyes with 3-oxo-2, 3-dihydrothiazole [3,2-a] pyrimidinium nucleus", <i>Ukrainskii Khimicheskii Zhurnal (Russian edition)</i> , <u>52</u> (5):514-19 (1986)
FT	STN (Chem. Abstracts) Document No. 66:105907, Chem. Abstract of French patent application FR1449800, "Sensitizing dyes", published 07/02/64.
FU	STN (Chem. Abstracts) Document No. 101:191838, Chem. Abstract of Russian language article by Fedotov <i>et al.</i> , "Mesoionic compounds with a nitrogen bridging atom. 12. Study of the cyclization of (2-pyrimidinylthio) acetic acids", <i>Khimiya Geterotsiklichesikh Soedinenii</i> , <u>7</u> :969-73 (1984)
FV	STN (Chem. Abstracts) Document No. 112:20939, Chem. Abstract of German language article by Augustin <i>et al.</i> , "Reactions of thiazolo [3,2-a] benzimidazol-3-one with electrophiles", <i>Zeitschrift fuer Chemie</i> , <u>29</u> (6):206-7 (1989)
FW	Tomkins, G.M., "The Metabolic Code", <i>Science</i> , <u>189</u> :760-763 (1975)
FX	Tsien, R.Y., "The Green Fluorescent Protein", <i>Annu. Rev. Biochem.</i> , <u>67</u> :509-544 (1998)
FY	Turner <i>et al.</i> , "Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: Current status and therapeutic possibilities", <i>Progress in Drug Research</i> , <u>51</u> :33-94 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**



PTO-1449

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

ATTY. DOCKET NO.
38205-3001B

SERIAL NO.
10/717,049

CONFIRM NO.
Unassigned.

APPLICANT
Martin *et al.*

CUSTOMER NO.
24961

FILING DATE
November 18, 2003

GROUP
Unassigned.

* If an asterisk is placed beside the reference number, a copy is provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

** If an asterisk is placed beside the reference number, a copy is NOT provided because pursuant to the USPTO's waiver from the 37 CFR 1.98(a)(2)(i) requirement for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b).

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

FZ	UKPDS 28: A Randomized Trial of Efficacy of Early Addition of Metformin in Sulfonylurea-Treated Type 2 Diabetes", <i>Diabetes Care</i> , <u>21(1)</u> :87-92 (1998)
GA	Urizar <i>et al.</i> , "The Farnesoid X-activated Receptor Mediates Bile Acid Activation of Phospholipid Transfer Protein Gene Expression", <i>Journal of Biological Chemistry</i> , <u>275(50)</u> :39313-39317 (2000)
GB	Van Allan, J.A., "2-Carboxymethylmercaptobenzimidazole and Related Compounds", <i>J. Org. Chem.</i> , <u>21</u> :24-27 (1956)
GC	Wan <i>et al.</i> , "Hepatocyte-Specific Mutation Establishes Retinoid X Receptor α as a Heterodimeric Integrator of Multiple Physiological Processes in the Liver", <i>Molecular and Cellular Biology</i> , <u>20(12)</u> :4436-4444 (2000)
GD	Wang <i>et al.</i> , "Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR", <i>Molecular Cell</i> , <u>3</u> :543-553 (1999)
GE	Willy <i>et al.</i> , "LXR, a nuclear receptor that defines a distinct retinoid response pathway", <i>Genes and Development</i> , <u>9</u> :1033-1045 (1995)
GF	Wilson <i>et al.</i> , "Disorders of Lipid Metabolism", Chapter 23, <i>Textbook of Endocrinology</i> , 9th Edition, (W.B. Sanders Company, Philadelphia, Pa., U.S.A.), 1998
GG	Yalpani <i>et al.</i> , "Cholesterol-Lowering Drugs", <i>Chemistry and Industry</i> , pp.85-89 (5 February 1996)
GH	Zhou <i>et al.</i> , "Nuclear Receptors Have Distinct Affinities for Coactivators: Characterization by Fluorescence Resonance Energy Transfer", <i>Molecular Endocrinology</i> , <u>12(10)</u> :1594-1604 (1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS**